Abbott Withdraws Psoriasis Drug Application
Abbott Laboratories is withdrawing its U.S. and European applications for experimental psoriasis drug briakinumab, citing regulators request for more research.
Abbott Laboratories is withdrawing its U.S. and European applications for experimental psoriasis drug briakinumab, citing regulators request for more research.